News | January 13, 2014

Study Shows Radiotherapy After Mastectomy Does Not Affect Mechanism in AeroForm Expander

airxpanders aeroform tissue expander radiation therapy
January 13, 2014 — AirXpanders Inc., a developer of technology for women who require tissue expansion for breast reconstruction following a mastectomy, announced new data published in The Journal of Radiation Oncology that demonstrates the AeroForm Tissue Expander can withstand radiation levels well above the maximum dose level typically used in post-mastectomy radiation therapy.
 
"Once a woman undergoes a mastectomy, she may still have to undergo radiation therapy. AeroForm offers women a more gradual, patient-controlled option for expansion, and I'm pleased to see that the device is unaffected even by extremely high levels of radiation," said James Rembert, M.D., radiation oncologist. Alta Bates Summit Comprehensive Cancer Center, Berkeley, Calif. "It is further proof that women who require additional radiation can feel confident that the AeroForm will not be impacted, so that they can continue to make progress towards regaining their shape even while continuing to receive treatment."
 
The study determined that the electronics inside the AeroForm expander continued to function properly after exposure to radiation levels up to 75 Gy — well above the maximum dose level (50-60 Gy). Following radiation exposure, 32 tissue expanders were functionally tested, and each successfully established communication with the dosage controller and deliver three CO2 doses according to product specifications.
 
A second, separate poster presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting by Jeffrey Kuo, M.D., University of California, Irvine. He demonstrated that the AeroForm expander did not significantly impede the delivery of radiation doses compared to dosing in breast cancer patients who have intact breasts. Results showed that measured skin doses varied only from -12 to +12 percent and suggested that computed tomography (CT) scans can help optimize dose variation.
 
"This data confirms that AeroForm is not adversely affected by radiation therapy, and there is minimal interference in the delivery of radiotherapy with an AeroForm implant in place," said Scott Dodson, president and CEO, AirXpanders. "As with all tissue expanders, the decision to use radiotherapy in conjunction with a tissue expander is at the discretion of the radiation oncologist and plastic surgeon. We are diligently working towards regulatory approval in Australia and expect to complete U.S. trial enrollment by the end of the year."
 

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init